Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my "No Doz Opportunity No. 1."
Somewhat ironically, a rollover in biotech stocks was one of the proximate causes of the overall sell-off in tech earlier this year.
And now I'm recommending that you invest in the company that purportedly "caused" the biotech market to roll over in the first place.
That's because this company will be the biggest beneficiary of biotech's comeback.
I bet you never knew irony could make you rich…
Bet on the Goat
Before I tell you more about this company, let's review biotech's recent fortunes.
Following a blistering run that saw it more than triple in less than three years, the bellwether Nasdaq Biotechnology Index (NBI) fell more than 20% from its late February high to mid-April. And the company I'm talking about today declined by almost exactly same amount during that period.
Since then, the NBI has quietly rallied to gain nearly 15% from its April 14 closing low. And the index is up nearly 8.9% for the year, nearly 70% better than the 5.25% gain the Standard & Poor's 500 posted during the same period.
Now I'm going to tell you the inside story behind biotech's rollover earlier this year.
And then I'm going to share with you the one company – like I said, the rollover's goat – that stands to gain the most as biotech stocks keep climbing.
Politics as Usual
Instead of being based on industry earnings reports or regulatory news, much of the recent biotech rollover had its roots in Washington meddling. Back in late March, several members of the U.S. House of Representatives wrote to a leading biotech company complaining about the high cost of its new drug.
Of course, the mainstream media ran hard with this congressional criticism – widely publicizing the letter and amplifying complaints about the high price of drugs.
Then, piling on, the financial media "discovered" biotech stocks… and trumpeted any news that showed them under duress.
If there's one thing I've learned in my 30 years as a tech investor, it's that such adversity often shines a light on fantastic opportunities.
Despite all the recent media noise, biotech faces a very bright long-term future. The industry keeps coming up with new drugs at a time when an aging population practically guarantees improving sales.
In other words, this is a decades-long trend backed by growing demand and solid fundamentals.
And the company I'm going to tell you about now is not only a perfect example of what I'm talking about, but it's on a path to crush the market from here.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
Leave a Reply